Details of the Drug Combinations

General Information of This Drug (ID: DM3O8QY)

Drug Name

Degarelix DM3O8QY

Synonyms

Degarelix; 214766-78-6; UNII-SX0XJI3A11; SX0XJI3A11; CHEMBL415606; Uglypeptide1; Degarelix (INN/USAN); Degarelix [USAN:INN:BAN]; SCHEMBL1397034; GTPL5585; HSDB 7817; CHEBI:135961; HY-16168A; BDBM50102450; AKOS030526717; AN-5181; RL02641; DB06699; CS-5350; FE200486 (AS ACETATE SALT); QC-10170; Z-3147; D08901; 766D786; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

12 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Degarelix + Leuprolide	DCCTGA6	Leuprolide	Metastatic Castration Sensitive Prostate Cancer (mCSPC)	[2]
Degarelix + Bay 80-6946	DC21GOX	Bay 80-6946	Prostate Cancer	[3]
Degarelix + Olaparib	DC44MFQ	Olaparib	Prostate Cancer	[4]
Degarelix + Enzalutamide	DC5WV96	Enzalutamide	Prostate Cancer	[5]
Degarelix + LY2835219	DCNMY6P	LY2835219	Male Breast Cancer	[6]
Degarelix + Arn-509	DC3H2SN	Arn-509	Prostate Cancer	[7]
Degarelix + Letrozole	DCBT079	Letrozole	Breast Cancer Invasive Nos	[8]
Degarelix + Darolutamide	DCFZAHV	Darolutamide	Prostate Cancer	[9]
Degarelix + Anastrozole	DCPYA1K	Anastrozole	Male Breast Cancer	[6]
Degarelix + Docetaxel	DCRLEVT	Docetaxel	Metastatic Prostatic Adenocarcinoma	[10]
Degarelix + Enzalutamide	DCY0KBT	Enzalutamide	Prostate Cancer	[5]
Trametinib + Degarelix	DCOI6AY	Trametinib	Prostate Cancer	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 12 DrugCom(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5585).
2	ClinicalTrials.gov (NCT05701007) Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
3	ClinicalTrials.gov (NCT06218667) A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer
4	ClinicalTrials.gov (NCT02324998) Study of Olaparib ( Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
5	ClinicalTrials.gov (NCT01990196) Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
6	ClinicalTrials.gov (NCT05501704) ETHAN - ET for Male BC
7	ClinicalTrials.gov (NCT03080116) Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
8	ClinicalTrials.gov (NCT02005887) TRial on the Endocrine Activity of Neoadjuvant Degarelix
9	ClinicalTrials.gov (NCT04176081) Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
10	ClinicalTrials.gov (NCT03069937) Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.